Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open, Non-Comparative, Phase III Study on the Efficacy, Pharmacokinetics and Safety of Two Injections of Triptorelin Embonate 22.5 mg 6-Month Formulation in Patients With Advanced Prostate Cancer

Trial Profile

A Multicenter, Open, Non-Comparative, Phase III Study on the Efficacy, Pharmacokinetics and Safety of Two Injections of Triptorelin Embonate 22.5 mg 6-Month Formulation in Patients With Advanced Prostate Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Debiopharm
  • Most Recent Events

    • 11 Mar 2010 The US FDA has approved the 6-month triptorelin formulation, according to a Watson pharmaceuticals media release. The approval is based on results from this trial.
    • 13 Oct 2009 Ipsen and Debiopharm announced that the 6-month triptorelin formulation has sucessfully completed the European decentralised registration procedure involving 9 European countries.
    • 25 Sep 2008 Debiopharm Group filing an MAA with the EMEA based on data from this trial, according to Debiopharm media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top